Epidemiological landscape of young multiple ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Epidemiological landscape of young multiple myeloma patients diagnosed earlier than 40 years: the french experience.
Auteur(s) :
Caulier, A. [Auteur]
Roussel, M. [Auteur]
Morel, Pierre [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Lombion, N. [Auteur]
Branco, B. [Auteur]
Galtier, J. [Auteur]
Hulin, C. [Auteur]
Perrot, A. [Auteur]
Richez, V. [Auteur]
Michaud-Robert, A. V. [Auteur]
Touzeau, C. [Auteur]
Doyen, C. [Auteur]
Mariette, C. [Auteur]
Caillot, D. [Auteur]
Harel, S. [Auteur]
Lenain, P. [Auteur]
Ivanoff, S. [Auteur]
Fontan, J. [Auteur]
Stoppa, A. M. [Auteur]
Manier, Salomon [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Garderet, L. [Auteur]
Leleu, X. [Auteur]
Marolleau, J. P. [Auteur]
Arnulf, B. [Auteur]
Avet-Loiseau, H. [Auteur]
Royer, B. [Auteur]
Roussel, M. [Auteur]
Morel, Pierre [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Lombion, N. [Auteur]
Branco, B. [Auteur]
Galtier, J. [Auteur]
Hulin, C. [Auteur]
Perrot, A. [Auteur]
Richez, V. [Auteur]
Michaud-Robert, A. V. [Auteur]
Touzeau, C. [Auteur]
Doyen, C. [Auteur]
Mariette, C. [Auteur]
Caillot, D. [Auteur]
Harel, S. [Auteur]
Lenain, P. [Auteur]
Ivanoff, S. [Auteur]
Fontan, J. [Auteur]
Stoppa, A. M. [Auteur]
Manier, Salomon [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Garderet, L. [Auteur]
Leleu, X. [Auteur]
Marolleau, J. P. [Auteur]
Arnulf, B. [Auteur]
Avet-Loiseau, H. [Auteur]
Royer, B. [Auteur]
Titre de la revue :
Blood
Nom court de la revue :
Blood
Numéro :
138
Pagination :
p. 2686–2695
Date de publication :
2021-12-23
ISSN :
1528-0020
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In ...
Lire la suite >Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age ≤40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P = .01), high ISS score (HR, 2.14; P = .03), and high-risk cytogenetics (HR, 4.54; P < .0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P < .0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sex-matched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.Lire moins >
Lire la suite >Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age ≤40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P = .01), high ISS score (HR, 2.14; P = .03), and high-risk cytogenetics (HR, 4.54; P < .0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P < .0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sex-matched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Date de dépôt :
2023-11-15T05:55:31Z
2023-12-06T12:52:36Z
2023-12-06T12:52:36Z
Fichiers
- bloodbld2021011285.pdf
- Accès libre
- Accéder au document